HanchorBio Expands Global Growth Strategy With Taiwan Listing and HCB101 Clinical Progress
TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026 HanchorBio, Inc. announced that the company will...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026 HanchorBio, Inc. announced that the company will...
March 3, 2026 Insilico Medicine, a clinical-stage biotechnology company known for its generative artificial intelligence platforms, has launched a...
OKLAHOMA CITY, Sept. 17, 2025 – Wheeler Bio, Inc., a U.S.-based contract development and manufacturing organization (CDMO), announced today...
